Manufacturers confirmed the recalled lots were counterfeit cancer and growth hormone drugs.
ANVISA determined the seizure of two lots of falsified medications: Keytruda (pembrolizumabe), lot Y020844, and Saizen (somatropina), lot AB003660. The manufacturers Merck Sharp & Dohme Farmacêutica Ltda and Merck S/A informed ANVISA they do not recognize these lots as their products. The action was formalized under Resolução RE 1.683/2026, published April 24, 2026.
Sources
Anvisa Recalls Falsified Keytruda, Saizen Lots
More from Pharma Drug Safety Browse all →
FDA Warns New Life Pharma for Manufacturing Unapproved GLP-1 Drugs
FDA issued a warning letter to New Life Pharma LLC for manufacturing and distributing unapproved Semaglutide and Tirzepatide products, citing CGMP violations and improper firm registration. The action targets the unauthorized production of drugs used in popular weight-loss treatments.
April 28, 2026
Three Class I Medical Device Recalls Hit Ventilators, Anesthesia Equipment
The FDA issued three Class I recalls in four days covering Draeger anesthesia workstations, Philips Trilogy Evo ventilators, and Phasitron respiratory valves—equipment used in surgical and critical care settings. The clustering of life-support equipment failures raises questions about supply chain quality control in medical device manufacturing.
April 18, 2026
FDA Warns Seven Companies for Selling Unapproved Peptide Drugs Online
Semaglutide copycats, Retatrutide, Tirzepatide sold without FDA approval through e-commerce
April 12, 2026
FDA Permanently Debars Five Individuals in One Day
Coordinated enforcement bars five from drug applications, signaling a fraud investigation sweep.
April 11, 2026
Get the briefing in your inbox
The top regulatory stories, delivered daily. No noise.
Free. Unsubscribe anytime.